OPT-302, a first-in-class VEGF-C/D ‘trap’ inhibitor, will be highlighted during the upcoming American Society of Retina Specialists (ASRS) 2023 Annual Meeting in Seattle, Washington. ASRS is the largest organisation of retina specialists in the world, with more than 3,000 members from 63 countries, and the annual meeting represents one of the largest United States conferences covering retinal diseases.
OPT-302 is the lead product candidate for the clinical stage biopharmaceutical company Opthea Limited. Currently in pivotal Phase 3 clinical trials, it is being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family. The goal is to improve overall efficacy and demonstrate superior vision gains over that which can be achieved by inhibiting VEGF-A alone.
During the scientific sessions at the ASRS conference, Dr Dante Pieramici (Director, California Retina Research Foundation, Partner, California Retina Consultants) will present new pharmacokinetics and pooled safety data on OPT-302 at the Pharmacology Symposium.
Opthea will also be featured in a wet age-related macular degeneration (wet AMD) key opinion leader (KOL) virtual fireside chat
Opthea will also be featured in a wet age-related macular degeneration (wet AMD) key opinion leader (KOL) virtual fireside chat discussing market trends and new treatments in wet AMD entitled, ‘Live from ASRS’.
The discussion will be hosted by Hartaj Singh, Managing Director and Senior Biotechnology Analyst at Oppenheimer & Co. Two world renowned retina disease experts, Dr Charles Wycoff MD, PhD (Director of Research at Retina Consultants of Texas, Chairman of Research, Retina Consultants of America, and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital) and Dr Dante Pieramici MD will serve as panelists alongside Dr Megan Baldwin, Opthea’s Chief Executive Officer.
Dr Baldwin commented, “At a time when most new wet AMD treatment candidates are largely focused on extending dosing treatment intervals in wet AMD, we look forward to sharing new data on the pharmacokinetics of OPT-302 to improve upon vision outcomes for patients above what is currently achieved with standard-of-care anti-VEGF-A monotherapy. Opthea is also appreciative of Oppenheimer for featuring the current global Phase 3 clinical program of OPT-302 and its potential value as a novel wet AMD treatment, as part of the hosted ‘Live from ASRS’ KOL forum.”
Dr Pieramici’s presentation, titled, Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases, the presentation will take place on 1 August from 9:10-9:14am AEST.
The Oppenheimer & Co sponsored ‘Live from ASRS’ wet AMD forum takes place on 2 August at 1am AEST, and can be accessed by registering at opco.zoom.us/webinar/register/WN_9HTx70FDRa6yIeUcEODn6w
